0001420520 false 0001420520 2020-10-29 2020-10-29 0001420520 2020-09-02 2020-09-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares










Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934


Date of report (Date of earliest event reported): October 29, 2020





(Exact Name of Registrant as Specified in Its Charter)




Delaware   001-37850   30-0509586
(State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification Number)


750 University Avenue, Suite 280

Los Gatos, California 95032

(Address of principal executive offices)


(408) 442-5248
(Registrant’s telephone number, including area code)


(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock: Par value $0.001 ATOM Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x





Item 2.02 Results of Operations and Financial Condition


On August 5, 2020, Atomera Incorporated issued a press release announcing its financial results for the three and nine months ended September 30, 2020. The Company also intends to conduct an earnings call over which it will distribute an investor presentation. The text of the press release is attached hereto as Exhibit 99.1 and the investor presentation is attached hereto as Exhibit 99.2, both are incorporated by reference herein.


The information in this Current Report, including the exhibits attached hereto, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act regardless of any general incorporation language in such filing.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits:


99.1 Press release dated October 29, 2020 Atomera Incorporated
99.2 Investor presentation dated October 29, 2020 Atomera Incorporated

































Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.



Dated: October 29, 2020 /s/ Francis B. Laurencio
  Francis B. Laurencio,
  Chief Financial Officer































Exhibit 99.1



Atomera Provides Third Quarter 2020 Results


LOS GATOS, Calif. — Oct. 29, 2020 — Atomera Incorporated (NASDAQ: ATOM), a semiconductor materials and intellectual property licensing company focused on deploying its proprietary technology into the semiconductor industry, today provided a corporate update and announced financial results for the third quarter ended Sept. 30, 2020.


Company Highlights


· Commenced MST deposition on 300mm wafers on new epi tool
· Achieved further gains on MST-SP’s industry leading performance
· Bolstered balance sheet with proceeds of At-The-Market (ATM) equity program


Management Commentary


“Atomera made excellent progress on customer and R&D developments in the third quarter,” said Scott Bibaud, President and CEO. “We believe we are drawing closer to a joint development agreement encompassing development, licensing and manufacturing, which we believe will decrease the time to commercialization of MST. As our 300mm wafer deposition capability comes online, paired with our new TCAD capabilities, we believe we are poised to accelerate customers’ time to production. With our ATM facility, we strengthened the balance sheet and positioned the Company for the next phase of growth.”


Third Quarter 2020 Financial Results


During the third quarter of 2020, revenue was $0, compared with $254 thousand in the third quarter of 2019. The Company incurred a net loss of $3.6 million, or ($0.19) per basic and diluted share, in the third quarter of 2020, compared to a net loss of $3.1 million, or ($0.19) per basic and diluted share, for the third quarter of 2019. Adjusted EBITDA (a non-GAAP financial measure) in the third quarter of 2020 was a loss of $2.7 million compared to an adjusted EBITDA loss of $2.4 million in the third quarter of 2019.


The Company had $25.3 million in cash and cash equivalents as of Sept. 30, 2020, compared to $14.9 million as of December 31, 2019. During the quarter, Atomera sold 845,730 shares under its ATM facility resulting in net proceeds of $8.6 million. The total number of shares outstanding was 21.0 million as of Sept. 30, 2020.


Third Quarter 2020 Results Conference Call and Webcast


Atomera will host a conference call today to discuss its financial results and recent progress.

Date: Thursday, Oct. 29, 2020

Time: 2:00 p.m. PT (5:00 p.m. ET)

Webcast: Accessible at www.atomera.com

Phone: (844) 263-8318 (domestic); +1 (213) 358-0960 (international); passcode 6268059

Replay: Available until Nov. 5, 2020; (855) 859-2056 (domestic); +1(404) 537-3406 (international); passcode 6268059.







Note about Non-GAAP Financial Measures

In addition to the unaudited results presented in accordance with generally accepted accounting principles, or GAAP, in this press release, Atomera presents adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is determined by taking net loss and eliminating the impacts of interest, depreciation, amortization and stock-based compensation. Our definition of adjusted EBITDA may not be comparable to the definitions of similarly-titled measures used by other companies. We believe that this non-GAAP financial measure, viewed in addition to and not in lieu of our reported GAAP results, provides useful information to investors by providing a more focused measure of operating results. This metric is used as part of the Company's internal reporting to evaluate its operations and the performance of senior management. A table reconciling this measure to the comparable GAAP measure is available in the accompanying financial tables below.


About Atomera Incorporated

Atomera Incorporated has developed Mears Silicon Technology™ ("MST®"), which increases performance and power efficiency in semiconductor transistors. MST can be implemented using equipment already deployed in semiconductor manufacturing facilities and is complementary to other nano-scaling technologies already in the semiconductor industry roadmap.


Safe Harbor

This press release contains forward-looking statements concerning Atomera Incorporated, including statements regarding the prospects for the semiconductor industry generally and the ability of our MST technology to significantly improve semiconductor performance. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (1) the fact that, to date, we have only recognized minimal engineering services and licensing revenues and we have not yet commenced principal revenue producing operations or entered into a definitive royalty-based manufacturing and distribution license agreement with regard to our MST technology, thus subjecting us to all of the risks inherent in an early-stage enterprise; (2) risks related to our ability to advance the licensing arrangements with our initial integration licensees, Asahi Kasei Microdevices, ST Microelectronics and our fabless licensee, to royalty-based manufacturing and distribution licenses or our ability to add other licensees; (3) risks related to our ability to raise sufficient capital, as and when needed, to pursue the further development, licensing and commercialization of our MST technology; (4) impact of the coronavirus pandemic on our customers, partners, internal operations and market conditions, including our ability to access financial markets on favorable terms, (5) our ability to protect our proprietary technology, trade secrets and know-how and (6) those other risks disclosed in the section "Risk Factors" included in our Prospectus Supplement filed pursuant to Rule 424(b)(5) with the SEC on September 2, 2020. We caution readers not to place undue reliance on any forward-looking statements. We do not undertake, and specifically disclaim any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.


-- Financial Tables Follow --
















Atomera Incorporated

Condensed Balance Sheets

(in thousands, except per share data)


    September 30,     December 31,  
    2020     2019  
Current assets:                
Cash and cash equivalents   $ 25,297     $ 14,871  
Prepaid expenses and other current assets     181       132  
Total current assets     25,478       15,003  
Property and equipment, net     87       63  
Operating lease right-of-use asset     735       161  
Long-term prepaid rent     450        
Security deposit     13       13  
Total assets   $ 26,763     $ 15,240  
Current liabilities:                
Accounts payable   $ 563     $ 315  
Accrued expenses     234       145  
Accrued payroll related expenses     511       819  
Current operating lease liability     92       152  
Deferred revenue           37  
Total current liabilities     1,400       1,468  
Long term operating lease liability     631        
Total liabilities     2,031       1,468  
Commitments and contingencies                
Stockholders’ equity:                
Preferred stock, $0.001 par value, authorized 2,500 shares; none issued and outstanding at September 30, 2020 and December 31, 2019.            
Common stock, $0.001 par value, authorized 47,500 shares; 20,971 and 17,117 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively.     21       17  
Additional paid-in capital     170,975       149,017  
Accumulated deficit     (146,264 )     (135,262 )
Total stockholders’ equity     24,732       13,772  
Total liabilities and stockholders’ equity   $ 26,763     $ 15,240  







Atomera Incorporated

Condensed Statements of Operations


(in thousands, except per share data)



Three Months ended

September 30,


Nine Months ended

September 30,

    2020     2019     2020     2019  
Revenue   $     $ 254     $ 62     $ 395  
Cost of revenue           (204 )     (13 )     (224 )
Gross margin           50       49       171  
Operating expenses                                
Research and development     2,049       1,746       6,197       5,930  
General and administrative     1,322       1,239       4,247       4,048  
Selling and marketing     208       240       648       712  
Total operating expenses     3,579       3,225       11,092       10,690  
Loss from operations     (3,579 )     (3,175 )     (11,043 )     (10,519 )
Other income                                
Interest income     1       89       41       265  
Total other income     1       89       41       265  
Net loss   $ (3,578 )   $ (3,086 )   $ (11,002 )   $ (10,254 )
Net loss per common share, basic and diluted   $ (0.19 )   $ (0.19 )   $ (0.61 )   $ (0.66 )
Weighted average number of common shares outstanding, basic and diluted     19,337       16,567       18,028       15,597  





Atomera Incorporated

Reconciliation to Non- GAAP EBITDA




Three Months Ended

September 30,


Nine Months Ended

September 30,

    2020     2019     2020     2019  
Net loss (GAAP)   $ (3,578 )   $ (3,086 )   $ (11,002 )   $ (10,254 )
Add (subtract) the following items:                                
Interest income     (1 )     (89 )     (41 )     (265 )
Depreciation and amortization     11       12       32       33  
Warrant modification                 139        
Stock-based compensation     829       798       2,224       2,280  
Adjusted EBITDA (non-GAAP)   $ (2,739 )   $ (2,365 )   $ (8,648 )   $ (8,206 )







Investor Contact:

Bishop IR

Mike Bishop

(415) 894-9633





































Exhibit 99.2


Q3 2020 Conference Call October 29, 2020 1


2 Safe Harbor This presentation contains forward - looking statements concerning Atomera Incorporated (““Atomera,” the “Company,” “we,” “us,” and “our”). The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward - looking statements. These forward - looking statements are subject to a number of risks, uncertainties and assumptions, including those disclosed in the section "Risk Factors" included in our Prospectus Supplement filed pursuant to Rule 424(b)(5)with the SEC on September 2, 2020. In light of these risks, uncertainties and assumptions, the forward - looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in our forward - looking statements. You should not rely upon forward - looking statements as predictions of future events. Although we believe that the expectations reflected in our forward - looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward - looking statements will be achieved or occur. This presentation contains only basic information concerning Atomera. The Company’s filings with the Securities Exchange Commission, including the Prospectus Supplement , include more information about factors that could affect the Company’s operating and financial results. We assume no obligation to update information contained in this presentation. Although this presentation may remain available on the Company's website or elsewhere, its continued availability does not indicate that we are reaffirming or confirming any of the information contained herein.


Mears Silicon Technology (MST®) Quantum Engineered Materials 3 Company Overview Strong, Growing and Defensible Patent Portfolio High Leverage IP Licensing Business Model Top Tier Management Team Transistor enhancement technology for the $450B semiconductor market 3


4 Customer Pipeline • 19 customers, 25 engagements • Working with 50% of the world’s top semiconductor makers* 0 3 6 9 12 15 18 21 24 27 IPO 3Q 16 4Q 16 1Q 17 2Q 17 3Q 17 4Q 17 1Q 18 2Q 18 3Q 18 4Q 18 1Q 19 2Q 19 3Q 19 4Q 19 1Q 20 2Q 20 3Q 20 Number of Customer Engagements Phase 1 Phase 2 Phase 3 * At least 10 of the top 20 (IC Insights, McClean Report 2019)


5 Customer engagement model v Customer Wafer Manufacturing Atomera MST ® Deposition Customer MST ® Deposition Phase 1 . Planning 2 . Setup 3 . Integration 4 . Installation 5 . Qualification 6 . Production Royalties Engineering Service Fees • MST deposition on customer wafers • Integration consulting License Fees • Integration licenses • Manufacturing licenses • Distribution licenses Joint Development Agreements


6 Atomera MSTcad ™ progress ⒒ Leading semiconductor companies use TCAD ⒒ MST is modelled with a TCAD add - on called MSTcad ⒒ These plots show silicon verification of MSTcad simulations ⒒ Enables good electrical match - up for 5V NMOS and MST SP ⒒ Should speed time to successful results with customers Atomera Confidential


7 300mm Epi tool Source: The McClean Report - 2019 300mm Epi Deposition Tool


8 Financial review FY 2019 Q1 '20 Q2 '20 Q3 '20 YTD 2020 GAAP Results Revenue $0.53M $0.06M -$ -$ $0.06M Gross Profit $0.28M $0.05M -$ -$ $0.05M Operating Expense R&D $7.7 $2.1M $2.1M $2.0M $6.2M G&A $5.2 $1.4M $1.5M $1.3M $4.2M S&M $1.0 $0.2M $0.2M $0.2M $0.6M Total Operating Expense $13.9M $3.7M $3.8M $3.6M $11.1M Net Loss ($13.3M) ($3.6M) ($3.8M) ($3.6M) $11.0M Loss Per Share ($0.84) ($0.22) ($0.21) ($0.19) ($0.62) Reconciliation between GAAP & Non-GAAP Net Loss (GAAP) ($13.3M) ($3.6M) ($3.8M) ($3.6M) ($11.0M) Stock-Based Compensation $2.9M $0.6M $0.8M $0.8M $2.2M Warrant Modification - $0.1M - - $0.1M Other income (expense) ($0.3M) - - - - Adjusted EBITDA (Non-GAAP)* ($10.7M) ($2.9M) ($3.0M) ($2.7M) ($8.6M) * Adjusted EBITDA is a non-GAAP financial measure. A full reconciliation of GAAP and non-GAAP results is contained in our Q3 press release. Some totals reflect rounding.


Thank You 9